Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status

This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities. In 17 patients (62–90 years old), the complete response rate was 47%, median progression-free survival was 5 months, and median overall survival was 21 months....

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2010-05, Vol.97 (3), p.389-392
Main Authors: Kurzwelly, Delia, Glas, Martin, Roth, Patrick, Weimann, Elke, Lohner, Hanns, Waha, Andreas, Schabet, Martin, Reifenberger, Guido, Weller, Michael, Herrlinger, Ulrich
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating - therapeutic use
Central Nervous System Neoplasms - drug therapy
Central Nervous System Neoplasms - genetics
Central Nervous System Neoplasms - mortality
Clinical Study - Patient Study
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
Disease-Free Survival
DNA Methylation - drug effects
DNA Modification Methylases - metabolism
DNA Repair Enzymes - metabolism
Female
Geriatrics
Humans
Lymphoma - drug therapy
Lymphoma - genetics
Lymphoma - metabolism
Male
Medicine
Medicine & Public Health
Middle Aged
Neurology
Oncology
Promoter Regions, Genetic - drug effects
Retrospective Studies
Survival Analysis
Tumor Suppressor Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities. In 17 patients (62–90 years old), the complete response rate was 47%, median progression-free survival was 5 months, and median overall survival was 21 months. Five of 17 patients (29.4%) had prolonged responses for at least 12 months and survived for more than 24 months. Three of these patients had a methylated O 6 -methylguanine-DNA methyltransferase (MGMT) promoter, while the MGMT status was not assessable in the remaining two patients. Temozolomide monotherapy appears to be effective in a subgroup of elderly PCNSL patients and deserves further evaluation.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-009-0032-0